RANBAXY LAUNCHES SOLITEN IN INDIA FOR TREATMENT OF UROLOGY DISORDER

Ranbaxy Laboratories Limited (Ranbaxy) announced the launch of its brand Soliten (Solifenacin), in the Indian market for the management of chronic urological disorder. The product is being introduced for the first time in India. Soliten will be sold in dosage forms of 5 mg and 10 mg tablets. Medical News Today (http://www.medicalnewstoday.com/medicalnews.php?newsid=50032&nfid=rssfeeds) (http://www.keralanext.com/news/index.asp?id=805965)